A plot to solve the ‘whack-a-mole’ of drug discovery
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Category: biotechnology
STAT+: Pfizer says 2024 profits will fall far below expectations
Pfizer said Wednesday that its 2024 profits would fall far below investor expectations, leading shares…
STAT+: Vertex non-opioid drug reduces chronic nerve pain in mid-stage study
Vertex Pharmaceuticals said Wednesday that an experimental drug reduced pain in people with diabetes who…
STAT+: Maze CEO ‘personally disappointed’ in Sanofi decision to terminate partnership
When Sanofi terminated its partnership with Maze Therapeutics this week to develop an experimental drug…
STAT+: A targeted therapy shows it can offer a ‘last, great chance’ for some acute leukemia patients
SAN DIEGO — One of the toughest subtypes of acute leukemia involves a genetic alteration…
Morning Rounds: Can you take GLP-1 drugs during pregnancy?
Understand how science, health policy, and medicine shape the world everyday. Sign up for our…
Tome Biosciences goes public today in another biotech megaround
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: With big ambition — and a family name to match — Reed Jobs charts his own course in biotech
In the months after his father died of complications from pancreatic cancer, Reed Jobs found…
STAT+: Sanofi ends deal for a rare disease drug after FTC voices monopoly concerns
In its latest bid to police the pharmaceutical industry, the U.S. Federal Trade Commission sought…
The biotech news you missed from the weekend
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: After sickle-cell screwups, Bluebird Bio’s only option might be a company sale
The approval Friday of Bluebird Bio’s gene therapy for sickle cell disease should have been…
STAT+: A Q&A with Vertex founder Joshua Boger on Casgevy, the biotech industry, and Elon Musk
Vertex Pharmaceuticals made history Friday when it received regulatory approval for a medicine that could…
STAT+: Historic approval of sickle cell gene therapies met with cautious optimism by experts at ASH
SAN DIEGO — News of the Food and Drug Administration’s historic approval of the first…
.jpg)
STAT+: Was CAR-T therapy a bystander or driver of lymphoma? Researchers examine first published case
SAN DIEGO — Researchers on Saturday presented an unusual case of a T cell lymphoma…
STAT+: Tough road ahead for Bluebird Bio despite FDA approval for sickle cell therapy
The Food and Drug Administration’s approval on Friday of two gene therapies for sickle cell…
STAT+: A Q&A with the CEO of CRISPR Therapeutics on a historic approval and the road ahead
Editas Medicine, CRISPR Therapeutics, and Intellia Therapeutics were all started in the 2013-2014 time frame…
In historic decision, FDA approves a CRISPR-based medicine for treatment of sickle cell disease
The Food and Drug Administration on Friday approved the world’s first medicine based on CRISPR…
Morning Rounds: 3D-printed organs, antimicrobial resistance in Ukraine, and other major health stories of the day
Understand how science, health policy, and medicine shape the world everyday. Sign up for our…
CRISPR is about to make history. Here’s the 5-minute rundown of what to expect
Want to stay on top of the science and politics driving biotech today? Sign up to get…
CRISPR history, biotech struggles, & a big week for deals
How does the first CRISPR treatment work? Can biotech rebound? And when is $300 million…
Diabetes ‘epidemic’ gets a Senate hearing
You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and…
Eli Lilly’s latest $1.4 billion deal might come unglued
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Sanofi says it has 12 blockbusters in its back pocket. Will investors believe it?
NEW YORK — The top executives at French drug giant Sanofi on Wednesday defended their…
STAT+: To lower drug prices, White House takes new aim at pharma patents
WASHINGTON — The White House is throwing its support behind a controversial authority that allows…
STAT+: AbbVie purchases neuroscience developer Cerevel for $8.7 billion
Abbvie announced Wednesday that it will purchase Cereval Therapeutics and its pipeline of experimental neurological…
Why Cerevel Therapeutics has risen 50% in three days without changing anything
Want to stay on top of the science and politics driving biotech today? Sign up to get…
New gene therapies confront many sickle cell patients with an impossible choice: a cure or fertility
As a teenager, Marie Tornyenu was always having to explain herself. If it wasn’t the…
STAT+: RNA startup ReNAgade cuts staff seven months after raising $300 million
Biotech startup ReNAgade Therapeutics is cutting staff just seven months after raising the largest Series…
Carmot’s chance of beating the odds in the biotech market just ended
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: BIO selects rare disease advocate, biotech executive John Crowley as new CEO
WASHINGTON — The Biotechnology Innovation Organization has chosen longtime biotech executive and rare disease advocate John…
STAT+: J&J to emphasize cancer drugs and stop much of its vaccine research
Eight months into his tenure, Johnson & Johnson’s R&D chief is putting a big emphasis…
STAT+: New CAR-T company, Brainchild Bio, will focus first on brain tumors in children
About a decade ago, Mike Jensen, a pediatric oncologist at Seattle Children’s hospital, licensed to…
STAT+: FDA efforts to oversee foreign drug manufacturing remain inadequate to ensure safety, analysis finds
In the wake of the Covid-19 pandemic, the Food and Drug Administration inspected far fewer…
Novartis is building a new radioligand plant in China
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: How sickle cell became the first disease treated by CRISPR
Nearly a decade ago, consultants delivered to Rodger Novak a kind of Sears catalog of…
Johnson & Johnson bets heavy on AI-driven drug discovery
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT Virtual Event – Decoding Clinical Trials: Venture Capitalists Talk Early Biotech R&D
Editor’s note: A livestream of the event will be embedded below at 1 p.m. ET….
AbbVie’s big deal, CAR-T’s risks, & getting a biotech job
Are ADCs having a moment? Is CAR-T safe? And who’s to blame for failed trials?…
Do GLP-1s have a future treating alcoholism?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: AbbVie buys Immunogen, maker of targeted cancer drugs, for $10 billion
AbbVie will pay $10 billion for the biotech firm Immunogen, the company said Thursday, acquiring…
STAT+: FDA chief scientist to replace Woodcock
WASHINGTON — The Food and Drug Administration’s chief scientist will replace retiring Janet Woodcock as principal…
Flagship Pioneering crosses the pond, opens a European front
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Saudi VC loops Novo Nordisk, other biotech VCs into new longevity incubator
The Hevolution Foundation, a Saudi investment firm focused on aging science, said Wednesday that it…
STAT+: Blood cancers may arise from CAR-T cells, but experts think only in very rare cases
The announcement on Tuesday that the Food and Drug Administration was investigating whether CAR-T immunotherapy…
STAT+: Scott Gottlieb, Trump FDA chief, questions whether there’s a Republican philosophy on health care
WASHINGTON — One of the Republican party’s most prominent health care thinkers doesn’t know what…
STAT+: FDA investigating whether CAR-T, a treatment for cancer, can also cause lymphoma
The Food and Drug Administration said Tuesday that it is investigating whether CAR-T therapy, which…
Today’s biotech news roundup, in under 800 words
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Argenx antibody fails study in platelet-destroying autoimmune disorder, derailing expansion plans
Belgium drugmaker Argenx said Tuesday that its antibody medicine failed to achieve the goals of…
How to spot when drug companies spin clinical trial results
Investors, analysts, doctors, and even patients face an avalanche of news from biotech companies about…
STAT+: Springworks wins FDA approval for drug to treat desmoid tumors
The Food and Drug Administration on Monday approved the first treatment for people with desmoid…